Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(7 sites)

United States

DM Clinical Research - Phoenix, Phoenix, Arizona

DM Clinical Research - MIA, Doral, Florida

Universal Axon Clinical Research (Rovia - UACR), Doral, Florida

Paramo Health, Miami, Florida

IMIC Research a Rovia Clinical Research Company, Miami, Florida

Paramo Health, Miami, Florida

UD Research, Atlanta, Georgia